Dorothy Scott, MD U.S. Food and Drug Administration

Dr. Scott is the Branch Chief for the Plasma Derivatives Branch, in the Office of Tissues and Advanced Therapies, CBER. Her group is responsible for regulation of 46 licensed products, including polyclonal Immune Globulins (IG), Alpha-1 Proteinase Inhibitor, C1 Esterase Inhibitors, and polyclonal antivenoms and antitoxins.

She received her M.D. degree at the University of Virginia, followed by residencies at Strong Memorial Hospital (University of Rochester), and University of Maryland. She completed her Rheumatology Fellowship at NIH in 1993. Since 1993, she has been a researcher and regulator in CBER. Her current research is focused upon passive immune therapy for influenza, Ebola virus antibody standards development, and on IG-mediated hemolysis.

Dr. Scott is also involved in regulatory and policy issues concerning product-specific adverse events, product supply, licensure of therapies under the Animal Efficacy Rule, antivenoms, medical countermeasures, and orphan product development.